Characterization of non-responders to interleukin-17 inhibitors in moderate to severe psoriasis patients enrolled in the Corrona^® Psoriasis Registry

J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e531-e533. doi: 10.1111/jdv.17270. Epub 2021 Apr 27.

Authors

J J Wu¹, D G Kearns², T-C Lin³, V S Chat⁴, H J Litman³, B Dube³, R R McLean³

Affiliations

¹ Dermatology Research and Education Foundation, Irvine, CA, USA.
² Loma Linda University School of Medicine, Loma Linda, CA, USA.
³ Corrona LLC, Waltham, MA, USA.
⁴ Medical College of Georgia at Augusta University, Augusta, CA, USA.

PMID: 33834554
DOI: 10.1111/jdv.17270

No abstract available

Publication types

Letter

MeSH terms

Humans
Interleukin-17*
Interleukin-23
Psoriasis* / drug therapy
Registries
Severity of Illness Index
Treatment Outcome

Substances

Interleukin-17
Interleukin-23

Grants and funding

National Psoriasis Foundation (NPF)